FDA grants accelerated approval to Augtyro for NTRK-positive solid tumors

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.
The indication applies to individuals with locally advanced or metastatic disease who have progressed despite previous treatment and lack alternative therapeutic options. It also applies to those who are likely to experience severe morbidity if they underwent surgical resection.
Repotrectinib (Augtyro, Bristol Myers Squibb) — a tyrosine kinase inhibitor (TKI) — previously received fast

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.
The indication applies to individuals with locally advanced or metastatic disease who have progressed despite previous treatment and lack alternative therapeutic options. It also applies to those who are likely to experience severe morbidity if they underwent surgical resection.
Repotrectinib (Augtyro, Bristol Myers Squibb) — a tyrosine kinase inhibitor (TKI) — previously received fast